Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series.

Autor:	Di Mauro G; Epilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 82, 00133, Rome, Italy.; Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 82, 00133, Rome, Rome, Italy., Vietri G; University of Rome Tor Vergata Department of Systems Medicine Rome Italy.; Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 82, 00133, Rome, Rome, Italy., Quaranta L; Division of Neurology and Stroke Unit, Epilepsy Centre, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy., Placidi F; Epilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 82, 00133, Rome, Italy.; Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 82, 00133, Rome, Rome, Italy., Izzi F; Epilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 82, 00133, Rome, Italy.; Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 82, 00133, Rome, Rome, Italy., Castelli A; Epilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 82, 00133, Rome, Italy.; Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 82, 00133, Rome, Rome, Italy., Pagano A; Epilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 82, 00133, Rome, Italy.; Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 82, 00133, Rome, Rome, Italy., Leonardis F; Department of Clinical Sciences and Translational Medicine, Intensive Care Unit, University of Rome 'Tor Vergata', Rome, Italy., De Angelis V; Department of Clinical Sciences and Translational Medicine, Intensive Care Unit, University of Rome 'Tor Vergata', Rome, Italy., Bianco C; Clinical Pharmacy, University Hospital of Rome 'Tor Vergata', Rome, Italy., Celeste MG; Clinical Pharmacy, University Hospital of Rome 'Tor Vergata', Rome, Italy., Mercuri NB; Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 82, 00133, Rome, Rome, Italy., Liguori C; Epilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 82, 00133, Rome, Italy.; Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 82, 00133, Rome, Rome, Italy.
Jazyk:	angličtina
Zdroj:	CNS & neurological disorders drug targets [CNS Neurol Disord Drug Targets] 2024 Jun 21. Date of Electronic Publication: 2024 Jun 21.
DOI:	10.2174/0118715273304077240603115521
Abstrakt:	Introduction: Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment of these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC). Case Presentation: Here, we present two cases of effective use of hpCBD in both refractory and super- refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures. Conclusion: According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu